Survey on Alopecia Areata Patients’ Reported Factors that Determine Severity of Alopecia Areata: A Nationwide Multicenter Study
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Alopecia areata (AA) is characterized by hair loss on the scalp and body, signifi- cantly impacting patients’ quality of life based on its severity. Objective: This study aims to identify crucial factors influencing the perception of severe AA from the patients’ viewpoint. Methods: A web-based survey was conducted among AA patients attending dermatology depart- ments at 21 university hospitals in Korea. The survey comprised 17 criteria, exploring both clin- ical characteristics of AA patients and subjective determinants of disease severity. Results: A total of 791 AA patients and their caregivers participated in the survey. Approxi- mately 30% of respondents developed AA during childhood, with 43.5% experiencing chronic courses lasting over 3 years. Half of the participants exhibited more than 20% scalp hair loss, and 42% reported additional hair loss on other body parts, such as eyelashes and nose hair. Most respondents agreed that patients with ≥20% scalp hair loss should be categorized as having severe AA. They also identified longer disease duration, involvement of non-scalp body hair, treatment refractoriness, and social or mental impairment requiring medical intervention as factors indicating increased disease severity. Conclusion: This survey underscores the significant impact of AA on patients’ quality of life and highlights existing unmet needs in current treatment modalities.
Abstract
Background: Alopecia areata (AA) is characterized by hair loss on the scalp and body, signifi- cantly impacting patients’ quality of life based on its severity. Objective: This study aims to identify crucial factors influencing the perception of severe AA from the patients’ viewpoint. Methods: A web-based survey was conducted among AA patients attending dermatology depart- ments at 21 university hospitals in Korea. The survey comprised 17 criteria, exploring both clin- ical characteristics of AA patients and subjective determinants of disease severity. Results: A total of 791 AA patients and their caregivers participated in the survey. Approxi- mately 30% of respondents developed AA during childhood, with 43.5% experiencing chronic courses lasting over 3 years. Half of the participants exhibited more than 20% scalp hair loss, and 42% reported additional hair loss on other body parts, such as eyelashes and nose hair. Most respondents agreed that patients with ≥20% scalp hair loss should be categorized as having severe AA. They also identified longer disease duration, involvement of non-scalp body hair, treatment refractoriness, and social or mental impairment requiring medical intervention as factors indicating increased disease severity. Conclusion: This survey underscores the significant impact of AA on patients’ quality of life and highlights existing unmet needs in current treatment modalities.
참고문헌 (33)
- Smith A, "High relapse rates despite early intervention with intravenous methylprednisolone pulse therapy for severe childhood alopecia areata", Pediatr Dermatol, 32, pp.481~487 (2015)
- Strazzulla LC, "Alopecia areata : disease characteristics, clinical evaluation, and new perspectives on pathogenesis", J Am Acad Dermatol, 78, pp.1~12 (2018)
- Chiang KS, "Clinical efficacy of diphenylcyclopropenone in alopecia areata : retrospective data analysis of 50 patients", J Investig Dermatol Symp Proc, 17, pp.50~55 (2015)
- Nowaczyk J, "Cyclosporine with and without systemic corticosteroids in treatment of alopecia areata : a systematic review", Dermatol Ther(Heidelb), 10, pp.387~399 (2020)
- Phan K, "Methotrexate for alopecia areata : a systematic review and meta-analysis", J Am Acad Dermatol, 80, pp.120~127 (2019)
- Strazzulla LC, "Alopecia areata : an appraisal of new treatment approaches and overview of current therapies", J Am Acad Dermatol, 78, pp.15~24 (2018)
- Yan D, "The efficacy and safety of JAK inhibitors for alopecia areata : a systematic review and meta-analysis of prospective studies", Front Pharmacol, 13, pp.950450~ (2022)
- King B, "Two phase 3 trials of baricitinib for alopecia areata", N Engl J Med, 386, pp.1687~1699 (2022)
- King B, "Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata : a randomised, double-blind, multicentre, phase 2b-3 trial", Lancet, 401, pp.1518~1529 (2023)
- Pazhoohi F, "Eyelash length attractiveness across ethnicities", Sci Rep, 13, pp.14849~ (2023)
- Sadr J, "The role of eyebrows in face recognition", Perception, 32, pp.285~293 (2003)
- Toussi A, "Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata : a systematic review", J Am Acad Dermatol, 85, pp.162~175 (2021)
- Villasante Fricke AC, "Epidemiology and burden of alopecia areata : a systematic review", Clin Cosmet Investig Dermatol, 8, pp.397~403 (2015)
- Wang LH, "Increased risk of suicide attempt in patients with alopecia areata : a nationwide population-based cohort study", Dermatology, 239, pp.712~719 (2023)
- Nguyen JV, "The biology, structure, and function of eyebrow hair", J Drugs Dermatol, 13(Suppl), pp.s12~s16 (2014)
- Starace M, "Impact and management of loss of eyebrows and eyelashes", Dermatol Ther(Heidelb), 13, pp.1243~1253 (2023)
- Ozturk AB, "Does nasal hair(vibrissae)density affect the risk of developing asthma in patients with seasonal rhinitis?", Int Arch Allergy Immunol, 156, pp.75~80 (2011)
- Lee S, "Comorbidities in alopecia areata : a systematic review and meta-analysis", J Am Acad Dermatol, 80, pp.466~477 (2019)
- Liu LY, "Health-related quality of life(HRQoL)among patients with alopecia areata(AA) : a systematic review", J Am Acad Dermatol, 75, pp.806~812 (2016)
- "Alopecia areata" (2023)[URL]
- "Alopecia areata" (2023)[URL]
- De Waard-van der Spek FB, "Juvenile versus maturity-onset alopecia areata--a comparative retrospective clinical study", Clin Exp Dermatol, 14, pp.429~433 (1989)
- Tosti A, "Alopecia areata : a long term follow-up study of 191 patients", J Am Acad Dermatol, 55, pp.438~441 (2006)
- Cranwell WC, "Treatment of alopecia areata : an Australian expert consensus statement", Australas J Dermatol, 60, pp.163~170 (2019)
- Rossi A, "Italian guidelines in diagnosis and treatment of alopecia areata", G Ital Dermatol Venereol, 154, pp.609~623 (2019)
- Ramos PM, "Consensus on the treatment of alopecia areata-Brazilian Society of Dermatology", An Bras Dermatol, 95(Suppl 1), pp.39~52 (2020)
- Tsuboi R, "Japanese Dermatological Association Alopecia areata clinical practice guidelines", Jpn J Dermatol, 127, pp.2741~2762 (2017)
- Mesinkovska N, "Burden of illness in alopecia areata : a cross-sectional online survey study", J Investig Dermatol Symp Proc, 20, pp.S62~S68 (2020)
- van Dalen M, "Anxiety, depression, and quality of life in children and adults with alopecia areata : a systematic review and meta-analysis", Front Med(Lausanne), 9, pp.1054898~ (2022)
- Manjaly P, "Development and validation of the Brigham Eyelash Tool for Alopecia(BELA) : a measure of eyelash alopecia areata", J Am Acad Dermatol, 85, pp.271~272 (2021)
- Tkachenko E, "Brigham eyebrow tool for alopecia : a reliable assessment of eyebrow alopecia areata", J Investig Dermatol Symp Proc, 20, pp.S41~S44 (2020)
- Wyrwich KW, "Development of clinician-reported outcome(ClinRO)and patient-reported outcome(PRO)measures for eyebrow, eyelash and nail assessment in alopecia areata", Am J Clin Dermatol, 21, pp.725~732 (2020)
- Park H, "Guidelines for the management of patients with alopecia areata in Korea : part I topical and device-based treatment", Ann Dermatol, 35, pp.190~204 (2023)